Nintedanib Teva Gmbh

Nintedanib, the active ingredient in Nintedanib Teva Gmbh, is a tyrosine kinase inhibitor presented as a capsule for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and is used with docetaxel in non‑small cell lung cancer.

GNH USA supplies Nintedanib Teva Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Nintedanib is indicated for fibrotic lung disorders and certain cancer regimens.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. - Non‑small cell lung cancer (in combination with docetaxel): enhances response rates and overall survival.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness or urge to vomit. - Vomiting: occasional episodes of expulsion of stomach contents. - Elevated liver enzymes: increase in ALT/AST observed in blood tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of arterial thromboembolism.

Before prescribing Nintedanib, clinicians should consider several precautionary measures.

- Liver function monitoring: assess ALT, AST, bilirubin before and during therapy. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy contraindication: avoid use in pregnant women; teratogenic risk. - Bleeding risk: evaluate patients with history of ulcers or anticoagulant use. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nintedanib can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise levels. - P-glycoprotein substrates (e.g., digoxin): potential altered concentrations. - Antacids or proton pump inhibitors: may affect absorption; monitor GI tolerance.